Alamea Verwaltungs GmbH Acquires New Stake in CME Group Inc. $CME

Key Points

• Alamea Verwaltungs GmbH has acquired a new stake in CME Group Inc., adding 3,292 shares valued at approximately $873,000, making it the firm's 14th largest holding.
• In recent analyst ratings, Oppenheimer raised their price target for CME Group from $300.00 to $303.00, while other firms like Citigroup and Barclays set targets of $275.00 and $298.00, respectively.
• CME Group recently announced a quarterly dividend of $1.25 per share, which translates to an annual yield of 1.9%, with a payout ratio of 48.40%.

Alamea Verwaltungs GmbH acquired a new stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,292 shares of the financial services provider's stock, valued at approximately $873,000. CME Group comprises 0.8% of Alamea Verwaltungs GmbH's portfolio, making the stock its 14th biggest holding.

Other hedge funds also recently bought and sold shares of the company. Heartland Bank & Trust Co purchased a new stake in CME Group during the first quarter valued at $377,000. Catalyst Capital Advisors LLC increased its position in CME Group by 256.9% during the first quarter. Catalyst Capital Advisors LLC now owns 3,662 shares of the financial services provider's stock valued at $971,000 after acquiring an additional 2,636 shares during the last quarter. OMNI 360 Wealth Inc. purchased a new stake in CME Group during the first quarter valued at $367,000. Fulcrum Equity Management purchased a new stake in CME Group in the first quarter worth about $258,000. Finally, AIA Group Ltd increased its position in CME Group by 17.8% in the first quarter. AIA Group Ltd now owns 16,645 shares of the financial services provider's stock worth $4,416,000 after buying an additional 2,510 shares in the last quarter. Hedge funds and other institutional investors own 87.75% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on CME shares. Oppenheimer upped their price target on CME Group from $300.00 to $303.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Barclays set a $298.00 price target on CME Group and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. UBS Group restated a "neutral" rating and issued a $305.00 price target on shares of CME Group in a research report on Thursday, July 24th. Citigroup upped their price target on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research report on Thursday, July 3rd. Finally, Erste Group Bank cut CME Group from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 24th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, CME Group has a consensus rating of "Hold" and a consensus target price of $261.93.

CME Group Stock Performance

NASDAQ:CME opened at $266.51 on Friday. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 12-month low of $207.75 and a 12-month high of $290.79. The stock has a 50-day moving average price of $275.64 and a 200 day moving average price of $269.36. The stock has a market capitalization of $96.04 billion, a P/E ratio of 25.80, a P/E/G ratio of 4.82 and a beta of 0.44.

CME Group (NASDAQ:CME - Get Free Report) last released its earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.91 by $0.05. CME Group had a return on equity of 14.60% and a net margin of 58.48%.The firm had revenue of $1.69 billion during the quarter, compared to analysts' expectations of $1.68 billion. During the same quarter last year, the business posted $2.56 earnings per share. The firm's revenue was up 10.4% on a year-over-year basis. Equities research analysts forecast that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 25th. Investors of record on Tuesday, September 9th will be given a dividend of $1.25 per share. The ex-dividend date is Tuesday, September 9th. This represents a $5.00 annualized dividend and a dividend yield of 1.9%. CME Group's dividend payout ratio (DPR) is currently 48.40%.

Insider Buying and Selling

In other CME Group news, Director William R. Shepard bought 256 shares of the business's stock in a transaction that occurred on Wednesday, June 25th. The stock was purchased at an average price of $270.53 per share, for a total transaction of $69,255.68. Following the completion of the transaction, the director owned 258,196 shares of the company's stock, valued at $69,849,763.88. This trade represents a 0.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sunil Cutinho sold 11,896 shares of the firm's stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $271.47, for a total value of $3,229,407.12. Following the transaction, the insider owned 17,440 shares of the company's stock, valued at $4,734,436.80. This represents a 40.55% decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.